In the continuing search for effective treatments for cancer, the emerging model is the combination of traditional chemotherapy with anti-angiogenesis agents1 that inhibit blood vessel growth. However, the implementation of this strategy has faced two major obstacles. First, the long-term shutdown of tumour blood vessels by the anti-angiogenesis agent can prevent the tumour from receiving a therapeutic concentration of the chemotherapy agent. Second, inhibiting blood supply drives the intra-tumoural accumulation of hypoxia-inducible factor-1α (HIF1-α); overexpression of HIF1-α is correlated with increased tumour invasiveness and resistance to chemotherapy2,3,4,5. Here we report the disease-driven engineering of a drug delivery system, a ‘nanocell’, which overcomes these barriers unique to solid tumours. The nanocell comprises a nuclear nanoparticle within an extranuclear pegylated-lipid envelope, and is preferentially taken up by the tumour. The nanocell enables a temporal release of two drugs: the outer envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner nanoparticle, which is trapped inside the tumour, then releases a chemotherapy agent. This focal release within a tumour results in improved therapeutic index with reduced toxicity. The technology can be extended to additional agents, so as to target multiple signalling pathways or distinct tumour compartments, enabling the model of an ‘integrative’ approach in cancer therapy.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kerbel, R. S. & Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nature Rev. Cancer 4, 423–436 (2004)
Semenza, G. L. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J. Clin. Invest. 106, 809–812 (2000)
Tran, J. et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 99, 4349–4354 (2002)
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J. & Kerbel, R. S. Effect of p53 status on tumour response to antiangiogenic therapy. Science 295, 1526–1528 (2002)
Blagosklonny, M. V. Antiangiogenic therapy and tumour progression. Cancer Cell 5, 13–17 (2004)
Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347–361 (2003)
Rofstad, E. K. et al. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 62, 1847–1853 (2002)
Kieran, M. W., Folkman, J. & Heymach, J. Angiogenesis inhibitors and hypoxia. Nature Med. 9, 1104 (2003)
Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727–739 (2002)
Chabner, B. A., et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th edn (McGraw-Hill, 1996)
Tozer, G. M., Kanthou, C., Parkins, C. S. & Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 83, 21–38 (2002)
Miklos, A. G., Lyman, M. D., Freed, L. E. & Langer, R. Wetting of poly(l-lactic acid) and poly(d-lactic-co-glycolic acid) foams for tissue culture. Biomaterials 15, 55–58 (1994)
Yoo, H. S., Oh, J. E., Lee, K. H. & Park, T. G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 16, 1114–1118 (1999)
Sengupta, S., Kiziltepe, T. & Sasisekharan, R. A dual-colour fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules. FASEB J. 18, 1565–1567 (2004)
Jain, R. K. Normalizing tumour vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7, 987–989 (2001)
Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J. Clin. Invest. 105, 1045–1047 (2000)
Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Drug Discov. 2, 750–763 (2002)
Yuan, F. et al. Vascular permeability in a human tumour xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752–3756 (1995)
Tong, R. T. et al. Vascular normalization by vascular endothelial growth facor receptor-2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731–3736 (2004)
Arap, W. et al. Steps toward mapping the human vasculature by phage display. Nature Med. 8, 121–127 (2002)
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)
We thank S. R. Kabir, K. Holley and G. T. Franzesi for assistance.
Reprints and permissions information is available at npg.nature.com/reprintsandpermissions. The authors declare no competing financial interests.
About this article
Cite this article
Sengupta, S., Eavarone, D., Capila, I. et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436, 568–572 (2005). https://doi.org/10.1038/nature03794
Expert Opinion on Drug Delivery (2021)
Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer
Frontiers in Oncology (2021)
Journal of Drug Targeting (2021)
Frontiers in Chemistry (2021)
Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect
Journal of Personalized Medicine (2021)